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Available online 11 August 2009The term thrombophilia describes an increased tendency to develop thrombosis and many laboratory
markers with different strengths of association with thrombosis have been identified. The main causes of
maternal mortality and morbidity in developed countries is venous thromboembolism (VTE) and obstetric
complications. During pregnancy and puerperium the risk for VTE increases due to hemostatic imbalance
towards a prothrombotic state, and it is further increased in women carriers of thrombophilia; recent studies
have also demonstrated an association between thrombophilia and obstetric complications. These
complications are, therefore, considered potentially preventable with the prophylactic administration of
anticoagulant drugs, although their efficacy is not proven by data from randomized controlled trials. After a
systematic comprehensive literature review and using a rigorous methodology, the expert panel formulated
recommendations regarding the usefulness of screening for thrombophilia in pregnancy to identify high-risk
women and for the management of antithrombotic prophyalxis. When evidence is lacking, consensus-based
recommendations are provided.
© 2009 Elsevier Ltd. All rights reserved.Introduction
Thrombophilia includes aheterogenous groupof inheritedoracquired
disorders that cause a tendency towards venous or arterial thrombosis
and it is associated with obstetric complications such as recurrent
pregnancy loss (RPL) (≥3, or 2 in the presence of at least one normal fetal
karyotype), unexplained intrauterine fetal death (IUFD), preeclampsia,
HELLP syndrome, fetal growth restriction (FGR) and abruptio placentae.
Thepathophysiologicmechanismsunderlying theassociationof inherited
thrombophilia and pregnancy complications are not at all clear and are
presumably related to vascular problems such as placenta thrombosis.
The association of thrombophilia and pregnancy complications is
controversial and limited by the small sample size of some studies.erale III, Ospedale San Paolo,
, Italy. Tel.: +39 0281844447;
ussana).
ll rights reserved.Identification of high-risk women is crucial in order to institute the
appropriate prophylaxis of these complications. Drugs that prevent
the formation of thrombosis are potentially useful and, based on the
association between thrombophilia and venous thrombosis and the
placenta-mediated pregnancy complications, women with a positive
history are advised about the indication for anticoagulant treatment
although the efficacy of heparins in this setting is not supported by
data from randomized controlled trials.
The objectives of these guidelines are to critically evaluate: i) the
usefulness of performing screening for thrombophilia to identify high-
risk women; ii) the tests to be included in thrombophilia screening for
pregnantwomen; iii) the optimalpharmacologicalmanagement inorder
to prevent venous thromboembolism (VTE) and obstetric complications.
Materials and Methods
The methodology used for developing SISET guidelines has been
previously reported [1]. The working group was composed of two
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medicine. The literature search to support the recommendations was
performed using the following sources: literature databases (MED-
LINE, EMBASE, Cochrane Library), reference lists of selected papers
and narrative reviews, editorials, guidelines and direct consultation
with field experts. The list of papers was updated in December 2008.
The Scottish Intercollegiate Guideline Network (SIGN) level of
evidence system was adopted for treatment issues [2] and that
proposed by the National Institute for Clinical Excellence (NICE) for
diagnostic issues [3]. In accordance with outstanding international
organizations, the SISET guidelines used the grading system proposed
by SIGN/NICE to formulate some evidence-based recommendations
and expertise-based recommendations when relevant areas could not
be addressed by the available evidence. The full body of recommenda-
tions was discussed and approved during 3 meetings held in Bologna
between June 2006 and May 2008.
Definitions
The present guidelines adapted the following definitions: 1)
Recurrent pregnancy loss: ≥3, or 2 in the presence of at least one
normal fetal karyotype; 2) Ante-partum: as soon as possible during
pregnancy.
Screening for Thrombophilia in Pregnancy
Maternal mortality due to hemorrage has been reduced in
developed countries, while VTE together with obstetric complications,
such as RPL, unexplained IUFD, preeclampsia, HELLP syndrome, FGR
and abruptio placentae are the main causes of maternal mortality and
morbidity. During pregnancy and puerperium the risk for VTE
increases due to hemostatic imbalance towards a prothrombotic
state and it is further increased in women carriers of thrombophilia
[4]. The incidence of VTE during pregnancy is 1 per 1.000 deliveries
[5–7], with a 5 fold increase during puerperium [5]. Pregnant women
carriers of thrombophilia have an increased risk of VTE by 3 to 52 fold
depending on the type of thrombophilic defect [4,8–11]. Thrombo-
philia is also associated with pregnancy complications and the
strength of this association is controversial depending on the type of
obstetric complication and of specific thrombophilia [12,13].
Due to the low prevalence of some types of thrombophilic
genotype and to the objective difficulty to perform research involving
pregnant women, the available literature is generally of poor quality.
In this sectionwe describe the results of a systematic literature review
and the recommendations for an appropriate use of thrombophilia
screening.Table 1
Association between inherited thrombophilia and pregnancy complications.
Meta-analysis VTE Recur
pregn
Factor V Leiden (heterozygous) Robertson et al. [14] 8.3 (5.4-12.7) 1.9 (1
Rey et al. [12] N.A. 2.0 (1
Kovalevsky et al. [15] N.A. 2.2 (1
Factor V Leiden (homozygous) Robertson et al. [14] 34.4 (9.8-120.1) N.A.
Prothrombin mutation (heterozygous) Robertson et al. [14] 6.8 (2.5-18.8) 2.7 (1
Rey et al. [12] N.A. 2.1 (1
Kovalevsky et al. [15] N.A. 2.5 (1
Prothrombin mutation (homozygous) Robertson et al. [14] 26.4 (1.2-559.3) N.A.
Antithrombin deficiency Robertson et al. [14] 4.7 (1.3-17.0) N.A.
Rey et al. [12] N.A. 0.9 (0
Protein C deficiency Robertson et al. [14] 4.8 (2.2-10.6) N.A.
Rey et al. [12] N.A. 1.6 (0
Protein S deficiency Robertson et al. [14] 3.2 (1.5-6.9) N.A.
Rey et al. [12] N.A. 14.7 (
§ recurrent first trimester; ⁎ before 13 weeks; N.A.= not applicable; APLA= antiphospholipTests to be included in the screening for thrombophilia, if testing is
indicated
Several studies, including systematic reviews and meta-ana-
lyses, evaluated the association between thrombophilia and VTE or
obstetric complications [12–22]. The meta-analyses of heteroge-
nous case-control studies suggest an increased prevalence in
women with pregnancy complications of the following thrombo-
philic defects: antithrombin deficiency, protein C deficiency, protein
S deficiency, factor V Leiden mutation (FVL), prothrombin 20210A
mutation (PTM), mild hyperhomocysteinemia and antiphospholi-
pid antibodies (APLA). We used as definition of APLA the criteria
established by the “International consensus statement on an update
of the classification criteria for definite antiphospholipid syndrome”
published in 2006 [23]. There is not enough evidence of association
between pregnancy complications and the following laboratory
tests: levels of FVIII, FIX, FXI, and FXII; polymorphisms of the FXIII,
MTHFR, and PAI-1 genes, and polymorphisms of the factor V or II
genes different from FVL or PTM. Table 1 summarizes the association
between inherited thrombophilia and pregnancy complications for
the tests suggested, reporting data from the more complete meta-
analyses.
Normal pregnancy is associated with major changes in hemostatic
balance and laboratory markers, such as the fall in free protein S levels
or the reduction in activated protein C (APC) sensitivity. For these
reasons it is preferable to perform thrombophilia tests, when possible,
before pregnancy.
Recommendation
We suggest including the following tests in the screening for
thrombophilia in pregnancy: antithrombin, protein C, protein S,
activated protein C resistance and/or FVL, PTM, homocysteine, APLA
(Grade A). It is advisable to perform screening for thrombophilia before
pregnancy. If the screening is performed during pregnancy the results
should be interpreted with great caution and in some cases completed
with a family study.
Testing asymptomatic women for thrombophilia
Universal screening for thrombophilia in pregnant women
A large number of studies in literature is available which includes
cohort studies and systematic reviews on the association between
thrombophilia and the risk of VTE and obstetric complications.
Systematic reviews are limited by the underlying published studies,
the majority of which are retrospective giving an estimate of the
magnitude of the increased risk of pregnancy complications which isrent
ancy loss
Unexplained
intrauterine death
Pre-eclampsia FGR Abruptio
.0-3.6)§ 2.1 (1.1-3.9) 2.2 (1.5-3.3) 2.7 (0.6-12.1) 4.7 (1.1-19.6)
.1-3.6)⁎ 3.3 (1.8-5.8) N.A. N.A. N.A.
.4-3.3) N.A. N.A. N.A. N.A.
2.0 (0.4-9.7) 1.9 (0.4-7.9) 4.6 (0.2-115.7) 8.4 (0.4-171.2)
.4-5.3)§ 2.7 (1.3-5.5) 2.5 (1.5-4.2) 2.9 (0.6-13.7) 7.7 (3.0-19.8)
.2-3.5) ⁎ 2.3 (1.1-4.9) N.A. N.A. N.A.
.3-4.7) N.A. N.A. N.A. N.A.
N.A. N.A. N.A. N.A.
7.6 (0.3-196.4) 3.9 (0.2-97.2) N.A. 1.1 (0.1-18.1)
.2-4.5) N.A. N.A. N.A. N.A.
3.1 (0.2-38.5) 5.2 (0.3-102.2) N.A. 5.9 (0.2-152.0)
.2-10.5) N.A. N.A. N.A. N.A.
20.1 (3.7-109.2) 2.8 (0.8-10.6) N.A. 2.1 (0.5-9.3)
1.0-218.0) N.A. N.A. N.A. N.A.
id antibodies; VTE: venous thromboembolism; FGR= fetal growth restriction.
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Therefore, the expert panel chose to base their evaluation on the
results of cohort studies performed in relatives of patients with a
particular thrombophilic defect [24–33]. The overall absolute risk of
VTE or obstetric complications is generally low; therefore, there is no
clear indication for performing mass screening for thrombophilia.
Indeed, the absolute risk of VTE in a woman carrier of FVL mutation is
about 0.8% and the absolute risk of obstetric complications is even
lower [14]. These conclusions are also supported by a systematic
review [13] inwhich a cost-effectiveness analysis was made and by an
economic study [34] both of which did not show a good cost-
effectiveness ratio of universal screening for thrombophilia. The
former two studies refer to the British National Health Service system.
Recommendation
We do not suggest screening for thrombophilia in asymptomatic
women without family history of VTE (Grade C).
Screening in asymptomatic women with family history of VTE or
obstetric complications
Evidence is lacking to recommend testing women with family
history of VTE or obstetric complications because there are no adequate
studies to support this approach. However, considering the demon-
strated association between thrombophilia and VTE, the expert panel
considered it potentially useful to test women with a family history of
VTE in order to identify individuals with severe thrombophilia, such as
antithrombin deficiency, ormultiple thrombophilic defects inwhich the
risk of pregnancy-associated complications is relevant.
Concerning obstetric complications, a retrospective study evalu-
ated the association between family history and the risk of pregnancy
complications [35] showing an increased risk of unexplained IUFD, but
the evidence of this study is limited by the retrospective design and
the small sample size.
Recommendations
We suggest screening for inherited thrombophilia in asymptomatic
women with family history of VTE (Grade D).
We do not suggest screening for thrombophilia in asymptomatic
women with family history of obstetric complications (Grade D).
Screening for thrombophilia in pregnant women with relatives with
inherited thrombophilia
Retrospective studies evaluated the riskof VTE in relatives of patients
with a thrombophilic defect and found a significant increased risk in
women carriers of a defect compared to non-carriers [9,10,28,36–39].
This association is considered particularly relevant for more severe
thrombophilic defects, such as natural anticoagulant deficiency, or
homozygous mutation or multiple thrombophilic defects [9,10,28,36–
39], although two very recent Italian studies failed to confirm this
association either in family members who are carriers of heterozygous
PTM [40] and in double heterozygous carriers of FVL and PTM [41].
Concerning obstetric complications, the level of evidence is limited to
FVL and to PTM [40,42,43]. It is difficult to establish if testing for
thrombophiliawas limited to the family defect or enlarged to a complete
screening. Someauthors suggested a possible advantage inperforming a
complete thrombophilia screening [44].
Recommendation
We suggest screening for inherited thrombophilia in asympto-
matic women with family history of inherited thrombophilia (Grade
C). It is suggested to search the family defect and at least the twomost
common mutations, FVL and PTM.Testing symptomatic women for thrombophilia
Screening for thrombophilia in pregnant women with previous VTE
Women who have VTE are at high risk for recurrent events and
whether the presence of a thrombophilic defect causes an additional
risk is controversial. The results of studies that examined the
relationship between hereditary thrombophilia and recurrent VTE
are conflicting, and the characteristics of the first thromboembolic
event seem to be the stronger predictor of recurrence than
thrombophilia per se. Women with a previous idiopathic VTE, or
pregnancy or estrogen-related event have a higher recurrence rate,
and antenatal anticoagulant prophylaxis is suggested independently
of the presence of thrombophilia [45–47]. Since the only available
prospective study [45] showed an increased risk of recurrence in
womenwho have thrombophilia and one study showed that standard
antithrombotic prophylaxis could be inadequate in the presence of
severe laboratory abnormality such as antithrombin deficiency [48],
the expert panel considers it useful to test for thrombophilia women
with a previous thromboembolic event for thrombophilia.
Recommendation
We suggest screening for thrombophilia in women with history of
VTE (Grade C).
Screening for thrombophilia in pregnant women with previous obstetric
complications
Several studies have demonstrated an association between
thrombophilia and obstetric complications, such as RPL, unexplained
IUFD, preeclampsia, HELLP syndrome, FGR and abruptio placentae
[12,13,16,20]. A possible association between thrombophilia and a first
pregnancy loss has also been shown [49]. Although in the absence of
robust studies it is difficult to establish the exact strength of these
associations, a stronger asssociation has been found between
thrombophilia and recurrent pregnancy loss or unexplained intrau-
terine death. Testing for thrombophilia may be considered useful to
evaluate the option for anticoagulant prophylaxis, even if based on
limited available studies of intervention [50,51] and until data from
ongoing controlled trials are published. Moreover, the expert panel
suggests considering two different grades of recommendation based
on the type of obstetric complication and specific thrombophilia.
Antiphoshpolipid antibodies are associated with recurrent preg-
nancy loss [22] and a recent Cochrane review showed the efficacy and
safety of thromboprophylaxis with aspirin and heparin in thesewomen
[52]. Hence, testing women with recurrent pregnancy loss for APLA is
suggested with a higher level of evidence.
Recommendations
We suggest screening for thrombophilia in women with recurrent
pregnancy loss or prior unexplained IUFD (Grade C).
We suggest screening for thrombophilia in women with prior
preeclampsia, HELLP syndrome, abruptio placentae, FGR (Grade D).
We suggest screening for APLA in women with recurrent
pregnancy loss (Grade B). Testing for antiphoshpolipid antibodies is
strongly suggested by the expert panel.
Role of Antithrombotic Prophylaxis
Pharmacological prophylaxis
The anticoagulant drugs normally used as antithrombotic prophy-
laxis are vitamin K antagonists and heparins. The former pass through
the placenta and are controindicated in pregnancy because of known
teratogenesis risk until the end of the first trimester of pregnancy and
because of cerebral haemorrhage risk for the foetus at the delivery due
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considering the shortness of the prophylaxis and the necessity to
obtain a therapeutic range, they are not particularly suitable.
Heparins do not pass through the placenta so they can be given
during pregnancy and puerperium. There are two systematic
reviews regarding the safety and efficacy of low molecular weight
heparin (LMWH) in pregnancy [54,55] and one Cochrane review
[56] on the prophylaxis of VTE in pregnancy which includes
studies both on LMWH and on unfractionated heparin (UFH). The
quality of these reviews is limited by the lack of randomized
clinical trials and they include above all small observational
studies. Moreover, the studies assessing risk and efficacy-safety
ratio of antithrombotic prophylaxis are heterogenous in terms of
heparin dosage and type of molecule. Only one randomized clinical
study directly compared LMWH vs UFH as prophylaxis in preg-
nancy [57]. The results of the aforementioned systematic reviews
showed a similar efficacy of both heparins, but LMWH resulted in a
safer profile compared to unfractioned heparin. Unfractioned
heparin seemstobeassociatedwithamild increased riskofhaemorrhage
and of symptomatic osteoporosis [58]. The risk of heparin-induced
thrombocytopenia (HIT) in pregnant women receiving LMWH is very
low; however, it is advisable to monitor platelet count after beginning of
prophylaxis.
There are no studies assessing the efficacy-safety ratio of new
anticoagulants in pregnancy.
Recommendation
LMWH should be preferred to UFH (Grade B). Monitoring platelet
count during prophylaxis with LMWH is advisable. LMWH is
preferable to vitamin K antagonists as antithrombotic prophylaxis
during puerperium. There is no evidence to suggest adjusting the
dosage of LMWH based on the levels of anti-Xa activity.
Dosages
The mentioned dosages of LMWH in the text are the following:
Prophylactic doses: dalteparin 5.000 IU sc od, or enoxaparin 40 mg
sc od, or nadroparin 3.800 IU sc od
Moderate doses: dalteparin 5.000 IU sc bd, or enoxaparin 40 mg sc
bd, or nadroparin 3.800 IU sc bd
Therapeutic doses: dalteparin 100 IU/kg sc bd, or enoxaparin 1mg/kg
sc bd, or nadroparin 92.7 IU/kg sc bd
The dosage of aspirin is 100 mg daily
Indication for antithrombotic prophylaxis in asymptomatic women with
thrombophilia
Management studies in asymptomatic women who have throm-
bophilia are rare, and therefore it is difficult to balance the absolute
risks of complications due to thrombophilia against the absolute
risks of the considered prophylactic measures. From retrospective
family studies the estimated risk of VTE in pregnancy is about 1/1000
[7,29,59] with a higher risk in the puerperium [7,59] and with a
further increase of the risk from 3 to 41 fold depending on the type of
thrombophilic defect present [8–11,24,28,37,60]. However, it is
worth noting that a recent Italian study did not find an increased
risk of first VTE during pregnancy and puerperium in double
heterozygous carriers of FVL and PTM compared to the risk of single
carriers [41].
The risk of anticoagulant prophylaxis with heparin is relatively low
and estimated for major bleeding lower than 0.5% [54,55]. The Expert
Panel considers that anticoagulant prophylaxis is not generally
justified and should be adapted based on the type of thrombophilicdefect; in particular, the presence of natural anticoagulant deficiencies
or combined thrombophilic defects, and the presence of other risk
factors. Risk factors for VTE in pregnancy and puerperium are those
reported in the guidelines of the Royal College of Obstetricians and
Gynaecologists [61]. In the absence of studies that directly examine
the risks of VTE and of anticoagulant prophylaxis in pregnancy the
following recommended strategies derive from formal consent of the
Expert Panel.
There are no studies to prove the potential benefits and risks of
antithrombotic prophylaxis in asymptomatic women with a family
history of VTE or obstetric complications. In the absence of evidence
the following recommendations are a consensus of the Expert Panel
according to the indication for prophylaxis of VTE.
The following recommendations apply to all asymptomatic
carrier women, with or without a family history of VTE or obstetric
complications.
Recommendations
We suggest prophylactic doses of LMWH ante-partum plus post-
partum for 6weeks after delivery inwomenwith no prior VTE and one
of the following thrombophilic defects: deficiency of protein C, protein
S, double heterozygous carriers of FVL and PTM or homozygous
carriers of FVL or PTM (Grade D).
We suggest moderate doses of LMWH ante-partum plus post-
partum for 6 weeks after delivery in women with no prior VTE and
deficiency of antithrombin (Grade D). At the time of delivery the use
of antithrombin concentrates should be evaluated, in order to allow
reduction of LMWH to prophylactic doses and decrease the haemor-
rhagic risk. The dosage warranted is 40 IU/Kg, to achieve a functional
circulating level of 0.8 U/ml of antithrombin.
We suggest surveillance or, in presence of additional risk factors
[61], ante-partum prophylactic doses of LMWH in women with no
prior VTE and heterozygous carriers of FVL or PTM. We also suggest
post-partum prophylactic doses of LMWH for 6 weeks after delivery
(Grade D).
We suggest ante-partumprophylactic doses of LMWHand/or aspirin
in asymptomatic women with APLA. We also suggest post-partum
prophylactic doses of LMWH for 6 weeks after delivery (Grade D).
It is advisable to refer women with natural anticoagulant
deficiency to specialized centres for a more precise diagnosis and for
correct counselling. Monitoring platelet count during prophylaxis
with LMWH is advisable. LMWH is preferable to vitamin K antagonists
as antithrombotic prophylaxis during puerperium.
Indication for antithrombotic prophylaxis in women with prior VTE
One prospective study assessed the risk of recurrence in
pregnant women with a history of VTE showing a risk of 6% in
women in which the first event was idiopathic and/or with a
thrombophilic abnormality [45]. In two retrospective studies the
risk of antepartum recurrent VTE was higher in women with a
previous idiopathic VTE, or pregnancy or estrogen-related event
[46,47]. Therefore, the cirumstances of any previous thromboem-
bolism and the type of thrombophilia should be considered, while
an universal antepartum prophylaxis is not warranted. Women
with high risk thrombophilia, such as natural anticoagulant defi-
ciency or combined defects may have a higher risk of recurrence
compared to women with lower risk thrombophilia [48]. The
available evidence on the efficacy of secondary prophylaxis with
heparin in pregnancy derives from 3 small randomized studies
[57,62,63] and from cohort studies [46,64–71] showing efficacy of
treatment. These studies are heterogeneous for study populations,
type of heparin used and dosages; therefore, the level of evidence
of efficacy should be considered moderate, but it is balanced by the
strong evidence of safety of LMWH in pregnancy [54,55].
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We suggest moderate doses of LMWH ante-partum plus post-
partum for 6 weeks after delivery inwomenwith prior VTE and one of
the following thrombophilic defects: deficiency of protein C, protein S,
double heterozygous carriers of FVL and PTM, homozygous carriers of
FVL or PTM, APLA. In women with APLA we suggest administering
ALSO ante-partum aspirin (Grade C).
We suggest therapeutic doses of LMWH ante-partum plus post-
partum for 6 weeks after delivery in women with prior VTE and
deficiency of antithrombin (Grade C). At the time of delivery the use of
antithrombin concentrates should be evaluated, in order to allow
reduction of LMWH to prophylactic doses and decrease the haemor-
rhagic risk. The dosage warranted is 40 IU/Kg, to achieve a functional
circulating level of 0.8 U/ml of antithrombin.
We suggest prophylactic doses of LMWH ante-partum plus post-
partum for 6 weeks after delivery in women with prior idiopathic or
estrogen or pregnancy related VTE and heterozygous carriers of FVL or
PTM (Grade C).
We suggest surveillance or, in the presence of additional risk
factors [61], ante-partum prophylactic doses of LMWH inwomenwith
prior VTE associated with a transient risk factor that is no longer
present and heterozygous carriers of FVL or PTM. We also suggest
post-partum prophylactic doses of LMWH for 6 weeks after delivery
(Grade C).
We suggest prophylactic doses of LMWH ante-partum plus post-
partum for 6 weeks after delivery in women without thrombophilia
and with prior idiopathic or estrogen or pregnancy related VTE
(Grade C).
We suggest surveillance or, in the presence of additional risk
factors [61], ante-partum prophylactic doses of LMWH in women
without thrombophilia with prior VTE associated with a transient risk
factor that is no longer present. We also suggest post-partum
prophylactic doses of LMWH for 6 weeks after delivery (Grade C).
Monitoring platelet count during prophylaxis with LMWH is
advisable. LMWH is preferable to vitamin K antagonists as antith-
rombotic prophylaxis during puerperium. Elastic stockings are
recommended in all women with previous VTE both in pregnancy
and puerperium.Indication for antithrombotic prophylaxis in women with prior obstetric
complications and thrombophilia
There are no studies that directly evaluated the potential benefits
of antithrombotic prophylaxis against the potential risks in women
with obstetric complications and one of the following thrombophilic
defects: deficiency of antithrombin, protein C, protein S, double
heterozygous carriers of FVL and PTM or homozygous carriers of FVL
or PTM. In the absence of studies the recommended strategies in these
conditions derive from formal consent of the Expert Panel according
to the indication for prophylaxis of VTE.
One study compared the use of prophylactic doses of LMWH and
aspirin in women with a single pregnancy loss and the presence of
heterozygous FVL or PTM, or deficiency of protein S showing benefit
from LMWH [50]. Another randomized controlled study of women
with recurrent pregnancy loss and thrombophilia (above all FVL or
PTM or the presence of APLA) compared two different doses of
enoxaparin resulting in a similar number in live birth rate in the two
arms of the study (84% in the group of enoxaparin 40mg daily and 78%
in the group of enoxaparin 40 mg twice daily) [51]. There are no data
from randomized controlled trials that evaluated benefits and risks of
prophylactic administration of heparin versus placebo in womenwith
previous pregnancy losses. Due to the absence of clinical trials the
same therapeutic uncertainty exists for women with other obstetric
complications and thrombophilia.A recent Cochrane review in women with RPL and APLA evaluated
the efficacy and risks of antithrombotic prophylaxis (heparin, aspirin
or both) showing benefit from treatment based on the combination of
aspirin and heparin [52].Recommendations
In the absence of specific studies, according to the indication for
prophylaxis of VTE, we suggest prophylactic doses of LMWH ante-
partum plus post-partum for 6 weeks after delivery in women with
prior obstetric complications and one of the following thrombophilic
defects: deficiency of protein C, protein S, double heterozygous
carriers of FVL and PTM or homozygous carriers of FVL or PTM
(Grade D).
In the absence of specific studies, according to the indication for
prophylaxis of VTE, we suggest moderate doses of LMWH ante-
partum plus post-partum for 6 weeks after delivery in asymptomatic
women with prior obstetric complications and deficiency of antith-
rombin (Grade D). At the time of delivery the use of antithrombin
concentrates should be evaluated, in order to allow reduction of
LMWH to prophylactic doses and decrease the haemorrhagic risk. The
dosage warranted is 40 IU/Kg, to achieve a functional circulating level
of 0.8 U/ml of antithrombin.
We suggest ante-partum prophylactic doses of LMWH in women
who are heterozygous carriers of FVL or PTM and had prior recurrent
pregnancy loss. According to the indication for prophylaxis of VTE we
also suggest post-partum prophylactic doses of LMWH for 6 weeks
after delivery (Grade C).
We suggest ante-partum prophylactic doses of LMWH in women
who are heterozygous carriers of FVL or PTM and and previously had
one of the following obstetric complications: unexplained IUFD,
preeclampsia, HELLP syndrome, abruptio placentae, FGR. According to
the indication for prophylaxis of VTE we also suggest post-partum
prophylactic doses of LMWH for 6 weeks after delivery (Grade D). In
the absence of evidence on the risk/benefit ratio of antithrombotic
prophylaxis in women with obstetric complications other than RPL or
IUFD, the aforementioned recommendation has been obtained using
RANDmethod [1]. We remark that one member of the Panel considers
the administration of antithrombotic prophylaxis incorrect and 3
members consider it uncertain.
We suggest ante-partum aspirin and prophylactic doses of LMWH
in women with recurrent pregnancy loss and APLA (Grade B).
We suggest ante-partum aspirin and prophylactic doses of LMWH
inwomenwith APLA and one of the following obstetric complications:
unexplained IUFD, preeclampsia, HELLP syndrome, FGR and abruptio
placentae (Grade D).
In the absence of specific studies, according to the indication for
prophylaxis of VTE, we also suggest post-partum prophylactic doses of
LMWH for 6 weeks after delivery in women with prior obstetric
complications and APLA (Grade D).Indication for antithrombotic prophylaxis in women with mild
hyperhomocysteinemia
In women who have mild hyperhomocysteinemia the use of folic
acid beyond the tenth week of gestation should be considered,
although this strategy is not supported by specific studies and the
recommendation derives from formal consent of the Expert Panel.Recommendations
We suggest the use of folic acid for the whole pregnancy inwomen
with mild hyperhomocysteinemia (Grade D).
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Review of the literature has highlighted the lack of good quality
studies both on the usefulness of thrombophilia tests and the efficacy
and safety of prophylaxis with anticoagulant drugs. The low
prevalence of some thrombophilic abnormalities makes it difficult to
carry out prospective clinical studies to estimate the risks of
thrombotic and obstetric complications for each single thrombophilic
defect. Moreover, the ethical problems connected with it have, up to
now, limited randomized clinical studies aimed at addressing the
safety and the efficacy of drug prophylaxis versus placebo. At present
there are some ongoing methodologically valid studies from which
important indications are expected.
The expert panel believes that clinical research in this field should
promote prospective studies to establish more accurately the
predictive value of thrombophilia tests for thromboembolic events
and obstetric complications. Moreover, randomized clinical trials of
treatment are needed to evaluate in women, with or without
thrombophilia, the efficacy of antithrombotic prophylaxis.
Finally, future studies should use homogenous definitions for the
different obstetric complications to obtain comparable and conclusive
results.
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